Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

Oral semaglutide, sold as Rybelsus, reduced the risk of a group of cardiovascular events by 14% compared with placebo in certain patients with Type 2 diabetes in a late-stage study, Novo said Monday.

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...

The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus ...